Bovine lactoferrin source anti-breast cancer small molecule peptide tablet and preparation method thereof

By obtaining and synthesizing small-molecular peptide tablets from the lactoferrin sequence, the problem of major side effects of breast cancer treatment is solved, and effective inhibition and safe treatment effect on breast cancer cells is achieved, filling the small-molecular peptide of milk protein source in the anti-aging area Research gaps in the field of cancer.

CN118903369AInactive Publication Date: 2024-11-08SHENZHEN SECOND PEOPLES HOSPITAL (SHENZHEN INST OF TRANSLATIONAL MEDICINE)
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202410945006.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-15
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art has great side effects in the treatment of breast cancer, and lacks understanding of the value of small-molecule peptides from milk protein in the field of anti-cancer, and lacks systematic research and innovation.

Method used

By obtaining from the lactoferrin sequence, the active peptide sequence was processed after gastrointestinal digestion, the online database was used to screen active peptides with inhibitory potential for breast cancer targets, and the Fmoc solid phase synthesis method was used to synthesize Small molecule peptides are mixed with curcumin, lycopene, catechin and dextrin to prepare tablets.

Benefits of technology

The prepared small-molecule peptide tablets of lactoferrin from the anti-breast cancer show obvious anti-breast cancer effects, inhibit the growth and spread of breast cancer cells, have small side effects and high safety, are suitable for auxiliary treatment, and can be classified according to different breast cancers. Make adjustments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903369A_ABST
    Figure CN118903369A_ABST
Patent Text Reader

Abstract

The invention discloses a bovine lactoferrin source anti-breast cancer small molecule peptide tablet and a preparation method thereof, and belongs to the technical field of biological medicines.The preparation method of the bovine lactoferrin source anti-breast cancer small molecule peptide tablet comprises the following steps that a bovine lactoferrin sequence is obtained; submitting the obtained bovine lactoferrin sequence to an online processing tool, and selecting pepsin and trypsin to hydrolyze bovine lactoferrin to obtain an active peptide sequence after gastrointestinal tract digestion; performing safety prediction on the obtained polypeptide sequence by using an online database; screening active peptides with inhibition potential on breast cancer related targets by using a molecular docking method; synthesizing a small molecule peptide; and preparing the small molecule peptide tablet. The bovine lactoferrin-derived anti-breast cancer small molecule peptide prepared by the invention shows relatively high anti-cancer activity through a synergistic effect with auxiliary components such as curcumin, lycopene, catechin and dextrin, and provides a brand new adjuvant therapy scheme for breast cancer patients.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and in particular relates to a bovine lactoferrin-derived anti-breast cancer small-molecule peptide tablet and a preparation method thereof. Background Art

[0002] Cancer, as a disease that poses a serious threat to human health, not only brings severe physical pain and discomfort, but also heavy psychological pressure, emotional distress and economic burden. Among many types of cancer, breast cancer is particularly concerning due to its high recurrence rate and metastasis risk. However, the treatment process of breast cancer is often accompanied by significant toxic side effects, which not only affect the patient's normal physiological functions, but also deeply affect the patient's psychological state. This makes the search for new treatment methods with less harm to the human body and high efficacy a key focus of scholars.

[0003] In recent years, small molecule peptides have gradually become the focus of research due to their diverse biological activities. These small molecule peptides have antioxidant, anti-inflammatory, anti-fatigue and immunomodulatory properties, which enable them to exhibit multiple regulatory functions in the human body. In addition, small molecule peptides also have obvious anti-tumor effects. While directly showing anti-tumor activity, they can also provide cancer patients with necessary energy and nutritional support. More importantly, small molecule peptides play an active role in reducing oxidative stress and inflammatory states, helping to alleviate the various side effects caused by tumors. In addition, small molecule peptides have extremely small toxic side effects and high patient compliance, which gives them unique advantages in anti-cancer treatment.

[0004] Although small molecule peptides have broad application prospects in the field of anti-cancer, the value of small molecule peptides derived from milk protein in anti-cancer is still insufficiently understood. Existing patents and research are mostly focused on drug treatment, while the method of alleviating the pain of cancer patients through dietary formulas has not received enough attention. In addition, the development and application of small molecule peptides in the field of anti-cancer functional foods is still in its infancy, lacking systematic research and innovation. Summary of the invention

[0005] In view of the problems and shortcomings of the above-mentioned prior art, the purpose of the present invention is to provide a bovine lactoferrin-derived anti-breast cancer small molecule peptide tablet and a preparation method thereof. The bovine lactoferrin-derived anti-breast cancer small molecule peptide tablet prepared by the present invention has excellent anti-breast cancer activity.

[0006] In order to solve the above technical problems, the technical solution adopted by the present invention is as follows:

[0007] A method for preparing a bovine lactoferrin-derived anti-breast cancer small molecule peptide tablet comprises the following steps:

[0008] S1. Acquisition of bovine lactoferrin sequence: The bovine lactoferrin sequence was obtained from NCBI;

[0009] S2, submitting the bovine lactoferrin sequence obtained in step S1 to an online processing tool, selecting pepsin and trypsin to hydrolyze the bovine lactoferrin to obtain active peptide sequences after gastrointestinal digestion;

[0010] S3, using online databases to predict the safety of the peptide sequences obtained in S2;

[0011] S4. Use molecular docking method to screen active peptides with inhibitory potential on breast cancer related targets;

[0012] S5, synthesis of small molecule peptides;

[0013] S6. Preparation of small molecule peptide tablets.

[0014] Preferably, the bovine lactoferrin sequence used in step S1 is as follows:

[0015] lactoferrin [Bos taurus] AAA21722.1 URL: https: / / www.ncbi.nlm.nih.gov / protein / AAA21722.1.

[0016] Preferably, the website of the online processing tool in S2 is: http: / / web.expasy.org / peptide_cutter / .

[0017] Preferably, in step S3, PeptideRanker, Toxinpred and Innovagen are used to predict the potential activity, toxicity, hydrophilicity, hydrophobicity, charge and solubility of the polypeptide sequence obtained in S2.

[0018] Further preferably, PeptideRanker (http: / / distilldeep.ucd.ie / Peptide Ranker / ) is used to predict the potential activity of peptides;

[0019] Toxinpred (http: / / www.imtech.res.in / raghava / toxinpred / ) is used to predict the toxicity, hydrophobicity, hydrophilicity, and charge of peptides;

[0020] Innovagen (http: / / www.innovagen.com / proteomics-tools) was used to predict the solubility of peptides.

[0021] Preferably, in S4, the molecular docking method is used to screen active peptides with inhibitory potential on breast cancer-related targets, comprising the following steps:

[0022] (1) Acquisition of 3D structures: The 3D structures of ERα, PR, HER2, and EGFR were obtained from the RCSB database (http: / / www.rcsb.org / pdb);

[0023] (2) Construction of active peptide structure: Use ChemDraw and Chem3D to construct active peptide structure;

[0024] (3) Molecular docking: After removing the ligands and water molecules from ERα, PR, HER2, and EGFR in step (1), nonpolar hydrogen and Gaussian charges were added together with the peptide sequence obtained in S2, and semi-flexible molecular docking of peptide with ERα, peptide with PR, peptide with HER2, and peptide with EGFR was performed using AutoDock 4.2 software;

[0025] (4) After molecular docking, active peptides that show the best binding to breast cancer-related targets were screened out based on the binding energy results.

[0026] Further preferably, the ERα is estrogen receptor α; PR is progesterone receptor; HER2 is human epidermal growth factor receptor 2; and EGFR is epidermal growth factor receptor.

[0027] Preferably, estrogen receptor positive (ER + ) The active peptides that showed the best binding in breast cancer were IW, RPY, AF, ADR, VY, TAGW, SAGW, VVW, EY, and EK.

[0028] Progesterone receptor positive (PR + ) The active peptides that showed the best binding in breast cancer were TAGW, SAGW, APVDA, VIPM, VPAL, VPVL, VVW, IW, EPY, and TW.

[0029] The active peptides that showed the best binding to HER2-positive breast cancer were QW, PEK, IW, EDL, VVW, VIPM, SW, VPAL, VY, and TW.

[0030] The active peptides that showed the best binding to triple-negative breast cancer were SAGW, VY, IW, AF, GY, SW, TAGK, AAH, VPVL, and TW.

[0031] Preferably, in S5, Shanghai Kepeptide Biotechnology Co., Ltd. uses the Fmoc solid phase synthesis method to synthesize the active peptides screened in step S4 into small molecule peptides.

[0032] Preferably, synthetic ER +The small molecule peptides that showed the best binding for breast cancer were IW, RPY, AF, ADR, VY, TAGW, SAGW, VVW, EY, and EK.

[0033] Synthetic PR + The small molecule peptides that showed the best binding for breast cancer were TAGW, SAGW, APVDA, VIPM, VPAL, VPVL, VVW, IW, EPY, and TW.

[0034] The synthesized small molecule peptides that showed the best binding to HER2-positive breast cancer were QW, PEK, IW, EDL, VVW, VIPM, SW, VPAL, VY, and TW.

[0035] The synthesized small molecule peptides that showed the best binding to triple-negative breast cancer were SAGW, VY, IW, AF, GY, SW, TAGK, AAH, VPVL, and TW.

[0036] The structural formula of the above small molecule peptide is as follows:

[0037]

[0038] Preferably, S6 is a mixture of one or more of the small molecule peptides synthesized in S5, curcumin, lycopene, catechins, and dextrin.

[0039] The present invention also provides bovine lactoferrin-derived anti-breast cancer small molecule peptide tablets prepared by the preparation method.

[0040] Preferably, the dosage form of the pharmaceutical agent is a tablet, which is prepared by mixing the above-mentioned substances, placing the mixture in a hopper, using a tablet press to tablet the mixture in the hopper, and taking out the tablets after tableting and packaging them.

[0041] Preferably, the tablet weighs 0.2-0.4 g.

[0042] Preferably, the tablet is used for adjuvant treatment of various types of breast cancer, including estrogen receptor positive, progesterone receptor positive, HER2 positive and triple negative breast cancer.

[0043] The invention provides a bovine lactoferrin-derived anti-breast cancer small-molecule peptide tablet, comprising the following components: 1-2 parts of small-molecule peptide, 1-3 parts of curcumin, 1-3 parts of lycopene, 1-3 parts of catechins and 4-20 parts of dextrin.

[0044] Take 1 part of the above small molecule peptides IW, RPY, AF, ADR, VY, TAGW, SAGW, VVW, EY, EK, or 2 parts of IW, RPY, AF, ADR, VY, respectively, and mix with 1-3 parts of curcumin, 1-3 parts of lycopene, 1-3 parts of resveratrol, 1-3 parts of catechins, and 4-20 parts of dextrin for adjuvant treatment of ER + Breast cancer.

[0045] Take 1 part of the above small molecule peptides TAGW, SAGW, APVDA, VIPM, VPAL, VPVL, VVW, IW, EPY, TW, or 2 parts of TAGW, SAGW, APVDA, VIPM, VPAL, and mix with 1-3 parts of curcumin, 1-3 parts of lycopene, 1-3 parts of catechins, and 4-20 parts of dextrin for adjuvant treatment of PR + Breast cancer.

[0046] Take 1 part of the above-mentioned small molecule peptides QW, PEK, IW, EDL, VVW, VIPM, SW, VPAL, VY, TW, or 2 parts of QW, PEK, IW, EDL, VVW, respectively, and mix them with 1-3 parts of curcumin, 1-3 parts of lycopene, 1-3 parts of catechins, and 4-20 parts of dextrin for adjuvant treatment of HER2-positive breast cancer.

[0047] Take 1 part of the above-mentioned small molecule peptides SAGW, VY, IW, AF, GY, SW, TAGK, AAH, VPVL, TW, or 2 parts of SAGW, VY, IW, AF, GY, respectively, and mix them with 1-3 parts of curcumin, 1-3 parts of lycopene, 1-3 parts of catechins, and 4-20 parts of dextrin for adjuvant treatment of triple-negative breast cancer.

[0048] Compared with the prior art, the present invention has the following beneficial effects:

[0049] 1. The present invention provides a method for preparing a bovine lactoferrin-derived anti-breast cancer small molecule peptide tablet, which exhibits obvious anti-breast cancer effects, promotes the in-depth development of small molecule peptides and their application in the medical field, and brings new auxiliary treatment solutions to the functional food and pharmaceutical fields.

[0050] 2. The tablets of the present invention have a significant inhibitory effect on the growth and spread of breast cancer cells through a specific small molecule peptide combination, and the tablets have small side effects and high safety. They can be used for adjuvant treatment of breast cancer and widely eliminate the side effects caused by breast cancer. At the same time, they can be adjusted according to the needs of patients with different breast cancer types to achieve better therapeutic effects.

[0051] 3. The preparation process of the tablets of the present invention is simple and easy, the active ingredients are clear, and it is convenient for industrial production, making it easier to market and apply.

[0052] The technical solution of the present invention is further described in detail below through the accompanying drawings and embodiments. BRIEF DESCRIPTION OF THE DRAWINGS

[0053] Figure 1 The effect of the bovine lactoferrin-derived anti-breast cancer small molecule peptide tablets provided in the control group and Examples 1-4 on the survival rate of MCF-7 cells;

[0054] Figure 2 The effect of the bovine lactoferrin-derived anti-breast cancer small molecule peptide tablets provided in the control group and Examples 1-4 on the survival rate of SK-BR-3 cells;

[0055] Figure 3 The effect of the bovine lactoferrin-derived anti-breast cancer small molecule peptide tablets provided in the control group and Examples 1-4 on the survival rate of HCC-1937 cells;

[0056] Figure 4 The effect of the bovine lactoferrin-derived anti-breast cancer small molecule peptide tablets provided in the control group and Examples 1-4 on the migration rate of MCF-7 cells;

[0057] Figure 5 The effect of the bovine lactoferrin-derived anti-breast cancer small molecule peptide tablets provided in the control group and Examples 1-4 on the migration rate of SK-BR-3 cells;

[0058] Figure 6 The effect of the bovine lactoferrin-derived anti-breast cancer small molecule peptide tablets provided in the control group and Examples 1-4 on the migration rate of HCC-1937 cells;

[0059] Figure 7 Statistical graph showing the effect of the bovine lactoferrin-derived anti-breast cancer small molecule peptide tablets provided in the model group and Examples 1-4 on the weight changes of mice;

[0060] Figure 8 The effect of the bovine lactoferrin-derived anti-breast cancer small molecule peptide tablets on tumor weight provided for the model group and Examples 1-4;

[0061] Fig. 9 A graph showing the effect of the bovine lactoferrin-derived anti-breast cancer small molecule peptide tablets on the tumor inhibition rate provided for the model group and Examples 1-4. DETAILED DESCRIPTION

[0062] The technical solution of the present invention is further described below through the accompanying drawings and embodiments.

[0063] Unless otherwise defined, technical or scientific terms used in the present invention shall have the common meanings understood by one having ordinary skills in the field to which the present invention belongs.

[0064] Example 1 This example provides a bovine lactoferrin-derived anti-ER + The small molecule peptide tablet for breast cancer comprises the following steps:

[0065] S1. Acquisition of bovine lactoferrin sequence: The bovine lactoferrin sequence was obtained from NCBI (the bovine lactoferrin number used: lactoferrin [Bos taurus] AAA21722.1 URL: https: / / www.ncbi.nlm.nih.gov / protein / AAA21722.1);

[0066] S2, submitting the bovine lactoferrin sequence obtained in step S1 to http: / / web.expasy.org / peptide_cutter / , selecting pepsin and trypsin to hydrolyze the bovine lactoferrin, and obtaining the active peptide sequence of the bovine lactoferrin after gastrointestinal digestion;

[0067] S3. Safety prediction of the peptide sequences obtained in S2 was performed using online databases: PeptideRanker (http: / / distilldeep.ucd.ie / Peptide Ranker / ) was used to predict the potential activity of peptides; Toxinpred (http: / / www.imtech.res.in / raghava / toxinpred / ) was used to predict the toxicity, hydrophobicity, hydrophilicity, and charge of peptides; Innovagen (http: / / www.innovagen.com / proteomics-tools) was used to predict the solubility of peptides. The screening results are shown in Table 1.

[0068] S4. Use molecular docking method to screen for ER + Active peptides with inhibitory potential for breast cancer related targets include the following steps:

[0069] (1) Acquisition of 3D structures: The 3D structures of ERα, PR, HER2, and EGFR were obtained from the RCSB database (http: / / www.rcsb.org / pdb);

[0070] (2) Construction of active peptide structure: Use ChemDraw and Chem3D to construct active peptide structure;

[0071] (3) Molecular docking: After removing the ligands and water molecules from ERα, PR, HER2, and EGFR in step (1), nonpolar hydrogen and Gaussian charges were added together with the peptide sequence obtained in S2, and semi-flexible molecular docking of peptide with ERα, peptide with PR, peptide with HER2, and peptide with EGFR was performed using AutoDock 4.2 software;

[0072] (4) After molecular docking, the active peptides IW, RPY, AF, ADR, VY, TAGW, SAGW, VVW, EY, and EK were screened out according to the binding energy results;

[0073] S5. Shanghai Kepeptide Biotechnology Co., Ltd. uses Fmoc solid phase synthesis method to synthesize small molecule peptides from the active peptides screened in step S4 to obtain IW, RPY, AF, ADR, VY, TAGW, SAGW, VVW, EY, and EK anti-ER + Small molecule peptides for breast cancer.

[0074] S6. Preparation of small molecule peptide tablets: Mix 1 part of the above IW, RPY, AF, ADR, VY, TAGW, SAGW, VVW, EY, and EK with 3 parts of curcumin, 3 parts of lycopene, 3 parts of resveratrol, 3 parts of catechins, and 5 parts of dextrin, put them in a hopper, and use a tablet press to tablet the mixture in the hopper. Take out the tablets after tableting and package them. The weight of the tablets is 0.2 g.

[0075] Example 2 This example provides a bovine lactoferrin-derived anti-PR + The small molecule peptide tablet for breast cancer comprises the following steps:

[0076] S1. Acquisition of bovine lactoferrin sequence: The bovine lactoferrin sequence was obtained from NCBI (the bovine lactoferrin number used: lactoferrin [Bos taurus] AAA21722.1 URL: https: / / www.ncbi.nlm.nih.gov / protein / AAA21722.1);

[0077] S2, submitting the bovine lactoferrin sequence obtained in step S1 to http: / / web.expasy.org / peptide_cutter / , selecting pepsin and trypsin to hydrolyze the bovine lactoferrin to obtain the active peptide sequence after gastrointestinal digestion;

[0078] S3. Safety prediction of the peptide sequences obtained in S2 was performed using online databases: PeptideRanker (http: / / distilldeep.ucd.ie / Peptide Ranker / ) was used to predict the potential activity of peptides; Toxinpred (http: / / www.imtech.res.in / raghava / toxinpred / ) was used to predict the toxicity, hydrophobicity, hydrophilicity, and charge of peptides; Innovagen (http: / / www.innovagen.com / proteomics-tools) was used to predict the solubility of peptides. The screening results are shown in Table 1.

[0079] S4. Use molecular docking method to screen PR + Active peptides with inhibitory potential for breast cancer related targets include the following steps:

[0080] (1) Acquisition of 3D structures: The 3D structures of ERα, PR, HER2, and EGFR were obtained from the RCSB database (http: / / www.rcsb.org / pdb);

[0081] (2) Construction of active peptide structure: Use ChemDraw and Chem3D to construct active peptide structure;

[0082] (3) Molecular docking: After removing the ligands and water molecules from ERα, PR, HER2, and EGFR in step (1), nonpolar hydrogen and Gaussian charges were added together with the peptide sequence obtained in S2, and semi-flexible molecular docking of peptide with ERα, peptide with PR, peptide with HER2, and peptide with EGFR was performed using AutoDock 4.2 software;

[0083] (4) After molecular docking, the active peptides TAGW, SAGW, APVDA, VIPM, VPAL, VPVL, VVW, IW, EPY, and TW were screened out according to the binding energy results;

[0084] S5. Shanghai Ketide Biotechnology Co., Ltd. uses Fmoc solid phase synthesis method to synthesize small molecule peptides from the active peptides screened in step S4 to obtain TAGW, SAGW, APVDA, VIPM, VPAL, VPVL, VVW, IW, EPY, and TW anti-PR + Small molecule peptides for breast cancer.

[0085] S6. Preparation of small molecule peptide tablets: Mix 1 part of the above-mentioned TAGW, SAGW, APVDA, VIPM, VPAL, VPVL, VVW, IW, EPY, and TW with 3 parts of curcumin, 3 parts of lycopene, 3 parts of catechins, and 5 parts of dextrin, put them in a hopper, and use a tablet press to tablet the mixture in the hopper. Take out the tablets after tableting and package them. The weight of the tablets is 0.2 g.

[0086] Example 3 This example provides a small molecule peptide tablet derived from bovine lactoferrin for anti-HER2 positive breast cancer, comprising the following steps:

[0087] S1. Acquisition of bovine lactoferrin sequence: The bovine lactoferrin sequence was obtained from NCBI (the bovine lactoferrin number used: lactoferrin [Bos taurus] AAA21722.1 URL: https: / / www.ncbi.nlm.nih.gov / protein / AAA21722.1);

[0088] S2, submitting the bovine lactoferrin sequence obtained in step S1 to http: / / web.expasy.org / peptide_cutter / , selecting pepsin and trypsin to hydrolyze the bovine lactoferrin to obtain the active peptide sequence after gastrointestinal digestion;

[0089] S3. Safety prediction of the peptide sequences obtained in S2 was performed using online databases: PeptideRanker (http: / / distilldeep.ucd.ie / Peptide Ranker / ) was used to predict the potential activity of peptides; Toxinpred (http: / / www.imtech.res.in / raghava / toxinpred / ) was used to predict the toxicity, hydrophobicity, hydrophilicity, and charge of peptides; Innovagen (http: / / www.innovagen.com / proteomics-tools) was used to predict the solubility of peptides. The screening results are shown in Table 1.

[0090] S4. Using molecular docking method, screening active peptides with inhibitory potential on HER2-positive breast cancer related targets, including the following steps:

[0091] (1) Acquisition of 3D structures: The 3D structures of ERα, PR, HER2, and EGFR were obtained from the RCSB database (http: / / www.rcsb.org / pdb);

[0092] (2) Construction of active peptide structure: Use ChemDraw and Chem3D to construct active peptide structure;

[0093] (3) Molecular docking: After removing the ligands and water molecules from ERα, PR, HER2, and EGFR in step (1), nonpolar hydrogen and Gaussian charges were added together with the peptide sequence obtained in S2, and semi-flexible molecular docking of peptide with ERα, peptide with PR, peptide with HER2, and peptide with EGFR was performed using AutoDock 4.2 software;

[0094] (4) After molecular docking, the active peptides QW, PEK, IW, EDL, VVW, VIPM, SW, VPAL, VY, and TW were screened out based on the binding energy results;

[0095] S5. Shanghai Kepeptide Biotechnology Co., Ltd. uses the Fmoc solid phase synthesis method to synthesize the active peptides screened in step S4 into small molecule peptides to obtain QW, PEK, IW, EDL, VVW, VIPM, SW, VPAL, VY, and TW anti-HER2-positive breast cancer small molecule peptides.

[0096] S6. Preparation of small molecule peptide tablets: Mix 1 part of the above QW, PEK, IW, EDL, VVW, VIPM, SW, VPAL, VY, TW with 3 parts of curcumin, 3 parts of lycopene, 3 parts of catechins, and 5 parts of dextrin, put them in a hopper, and use a tablet press to tablet the mixture in the hopper. Take out the tablets after tableting and package them. The weight of the tablets is 0.2 g.

[0097] Example 4 This example provides a bovine lactoferrin-derived small molecule peptide tablet for treating triple-negative breast cancer, comprising the following steps:

[0098] S1. Acquisition of bovine lactoferrin sequence: The bovine lactoferrin sequence was obtained from NCBI (the bovine lactoferrin number used: lactoferrin [Bos taurus] AAA21722.1 URL: https: / / www.ncbi.nlm.nih.gov / protein / AAA21722.1);

[0099] S2, submitting the bovine lactoferrin sequence obtained in step S1 to http: / / web.expasy.org / peptide_cutter / , selecting pepsin and trypsin to hydrolyze the bovine lactoferrin to obtain the active peptide sequence after gastrointestinal digestion;

[0100] S3. Safety prediction of the peptide sequences obtained in S2 was performed using online databases: PeptideRanker (http: / / distilldeep.ucd.ie / Peptide Ranker / ) was used to predict the potential activity of peptides; Toxinpred (http: / / www.imtech.res.in / raghava / toxinpred / ) was used to predict the toxicity, hydrophobicity, hydrophilicity, and charge of peptides; Innovagen (http: / / www.innovagen.com / proteomics-tools) was used to predict the solubility of peptides. The screening results are shown in Table 1.

[0101] S4. Using the molecular docking method, active peptides with inhibitory potential on triple-negative breast cancer related targets were screened, including the following steps:

[0102] (1) Acquisition of 3D structures: The 3D structures of ERα, PR, HER2, and EGFR were obtained from the RCSB database (http: / / www.rcsb.org / pdb);

[0103] (2) Construction of active peptide structure: Use ChemDraw and Chem3D to construct active peptide structure;

[0104] (3) Molecular docking: After removing the ligands and water molecules from ERα, PR, HER2, and EGFR in step (1), nonpolar hydrogen and Gaussian charges were added together with the peptide sequence obtained in S2, and semi-flexible molecular docking of peptide with ERα, peptide with PR, peptide with HER2, and peptide with EGFR was performed using AutoDock 4.2 software;

[0105] (4) After molecular docking, the active peptides SAGW, VY, IW, AF, GY, SW, TAGK, AAH, VPVL, and TW were screened out based on the binding energy results;

[0106] S5. Shanghai Kepeptide Biotechnology Co., Ltd. uses the Fmoc solid phase synthesis method to synthesize the active peptides screened in step S4 into small molecule peptides to obtain SAGW, VY, IW, AF, GY, SW, TAGK, AAH, VPVL, and TW anti-triple-negative breast cancer small molecule peptides.

[0107] S6. Preparation of small molecule peptide tablets: Mix 1 part of the above SAGW, VY, IW, AF, GY, SW, TAGK, AAH, VPVL, and TW with 3 parts of curcumin, 3 parts of lycopene, 3 parts of catechins, and 5 parts of dextrin, put them in a hopper, and use a tablet press to tablet the mixture in the hopper. Take out the tablets after tableting and package them. The weight of the tablets is 0.2 g.

[0108] Table 1 Prediction of active peptide properties

[0109]

[0110]

[0111]

[0112] Table 2 Binding energy of anticancer peptides and related target proteins

[0113]

[0114]

[0115]

[0116] The effects of the tablets provided in the above embodiments were verified by the following tests:

[0117] 1. To verify the effects of Examples 1-4 on the survival rates of MCF-7, SK-BR-3, and HCC-1937 cells, the experimental scheme was as follows: MCF-7, SK-BR-3, and HCC-1937 cells were cultured in a high-glucose formula medium supplemented with 10% (v / v) fetal bovine serum and 1% (v / v) penicillin-streptomycin at a culture temperature of 37°C and a carbon dioxide concentration of 5%.

[0118] CCK-8 assay: The viability of breast cancer cells was detected using the CCK-8 assay. Each breast cancer cell line (6 independent replicates) in the logarithmic growth phase was cultured at 5×10 3 The density of cells / well was inoculated into 96-well plates, and then incubated at 37°C overnight. 2.0 mg / mL of Examples 1-4 was added to the cell culture medium and treated for 24 hours, and PBS was used as a control. Then 10uL of CCK-8 solution reagent was added to each well and incubated for further 1 hour. The absorbance of the resulting solution was recorded at 450nm using an ELISA reader (Varioskan Flash 2.4, Thermo Fisher Scientific, USA), and cell viability was expressed as a percentage of the control group. The results are shown in Figure 1-Figure 3 .

[0119] Compared with the control group, the small molecule peptide tablets prepared in Example 1 can reduce the survival rates of MCF-7, SK-BR-3, and HCC-1937 cells to 5.21%, 6.94%, and 8.71%, respectively. The small molecule peptide tablets prepared in Example 2 can reduce the survival rates of MCF-7, SK-BR-3, and HCC-1937 cells to 7.65%, 7.05%, and 13.51%, respectively. The small molecule peptide tablets provided in Example 3 can reduce the survival rates of MCF-7, SK-BR-3, and HCC-1937 cells to 9.26%, 4.15%, and 10.83%, respectively. The small molecule peptide tablets prepared in Example 4 can reduce the survival rates of MCF-7, SK-BR-3, and HCC-1937 cells to 16.36%, 10.63%, and 5.68%, respectively.

[0120] 2. To verify the effect of Examples 1-4 on the migration rate of MCF-7, SK-BR-3, and HCC-1937 cells, the experimental scheme is as follows: MCF-7, SK-BR-3, and HCC-1937 cells were plated on a 6-well plate at 5×10 4 The cells were cultured at a density of 10 cells / well for 48 h. After reaching a density of 80%, the culture medium was aspirated, the cell monolayer was scraped with a 10 uL sterile pipette tip, and then gently washed with PBS to remove cell debris. Then, the cells were incubated with Examples 1-4, respectively, and their migration along the injury line was observed under a microscope. Cell images (5x magnification) were captured after 0 h, 24 h, and 48 h of incubation in Examples 1-4, and analyzed using ImageJ software (Maryland, USA). The results are shown in Figure 4-Figure 6 .

[0121] Compared with the control group, the small molecule peptide tablets prepared in Example 1 can reduce the migration rates of MCF-7, SK-BR-3, and HCC-1937 cells to 4.09%, 25.34%, and 12.15%, respectively; the small molecule peptide tablets prepared in Example 2 can reduce the migration rates of MCF-7, SK-BR-3, and HCC-1937 cells to 20.86%, 21.15%, and 15.51%, respectively. The small molecule peptide tablets provided in Example 3 can reduce the migration rates of MCF-7, SK-BR-3, and HCC-1937 cells to 15.70%, 8.09%, and 17.70%, respectively. The small molecule peptide tablets prepared in Example 4 can reduce the migration rates of MCF-7, SK-BR-3, and HCC-1937 cells to 12.64%, 15.48%, and 6.08%, respectively.

[0122] 3. To verify the effects of Examples 1-4 on tumor weight and tumor inhibition rate, the experimental protocol was as follows: BALB / c mice, female, 18-22 g, were purchased from Sibeifu (Beijing) Biotechnology Co., Ltd. The mice were kept at 25±1°C, 12h light / dark cycle, with free access to water and food, standard pellet diet, usually various grains or grain foods made from ingredients such as soybean meal, corn meal, fish meal and animal by-products. All experimental protocols were approved by the Animal Ethics Committee of Shenzhen Second People's Hospital and were carried out in accordance with the Principles for the Care and Use of Laboratory Animals.

[0123] Before the establishment of the cancer-induced fatigue animal model, mice were subjected to a weight-bearing swimming test, and the mice with the longest and shortest swimming time were eliminated. 6 cells / 0.1 mL / mouse) were injected subcutaneously into the second mammary fat pad on the left side of the mouse. When the tumor size reached 80-100 mm 3 Start treatment when

[0124] 50 mice were randomly assigned to five treatment groups (10 mice in each group). Model group: Oral administration of 0.9% saline every day, the average weight of mice before treatment was 25.29g. Group 1: Oral administration of the small molecule peptide tablets prepared in Example 1 every day, 200 mg per kilogram of body weight for each mouse, and the average weight of mice before treatment was 25.04g. Group 2: Oral administration of the small molecule peptide tablets prepared in Example 2 every day, 200 mg per kilogram of body weight for each mouse, and the average weight of mice before treatment was 24.21g. Group 3: Oral administration of the shaped small molecule peptide tablets prepared in Example 3 every day, 200 mg per kilogram of body weight for each mouse, and the average weight of mice before treatment was 24.19g. Group 4: Oral administration of the small molecule peptide tablets prepared in Example 4 every day, 200 mg per kilogram of body weight for each mouse, the treatment time was 13d, and the average weight of mice before treatment was 24.06g.

[0125] The tumor weight and tumor inhibition rate were measured on the mice in the above groups:

[0126] Tumor weight determination: After 13 days of treatment, the mice in groups 1 to 4 and the model group were killed and the tumors were removed and weighed.

[0127] Determination of tumor inhibition rate: Tumor inhibition rate = (AB) / A*100%, where A and B are the average tumor weights of mice in the model group and the corresponding treatment group after 13 days of treatment, respectively.

[0128] like Figure 7-9 As shown, after 13 days of treatment, the average body weights of mice in the first to fourth groups and the model group were measured, respectively: the average body weight of mice in the model group was 28.45 g, and the tumor weight was 1.29 g; the average body weight of mice in the first group was 29.18 g, the tumor weight was 0.82 g, and the tumor inhibition rate was 35.41%; the average body weight of mice in the second group was 28.84 g, the tumor weight was 1.07 g, and the tumor inhibition rate was 16.06%; the average body weight of mice in the third group was 28.83 g, the tumor weight was 0.80 g, and the tumor inhibition rate was 37.99%; the average body weight of mice in the fourth group was 29.12 g, the tumor weight was 0.95 g, and the tumor inhibition rate was 26.19%.

[0129] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that they can still modify or replace the technical solution of the present invention with equivalents, and these modifications or equivalent replacements cannot cause the modified technical solution to deviate from the spirit and scope of the technical solution of the present invention.

Claims

1. A method for preparing a bovine lactoferrin-derived anti-breast cancer small molecule peptide tablet, characterized in that: The following steps are involved: S1. Acquisition of bovine lactoferrin sequence: The bovine lactoferrin sequence was obtained from NCBI; S2, submitting the bovine lactoferrin sequence obtained in step S1 to an online processing tool, selecting pepsin and trypsin to hydrolyze the bovine lactoferrin to obtain active peptide sequences after gastrointestinal digestion; S3, using online databases to predict the safety of the peptide sequences obtained in S2; S4. Use molecular docking method to screen active peptides with inhibitory potential on breast cancer related targets; S5. Synthesis of small molecule peptides; S6. Preparation of small molecule peptide tablets.

2. The preparation method according to claim 1, characterized in that: In step S3, PeptideRanker, Toxinpred and Innovagen were used to predict the potential activity, toxicity, hydrophilicity, hydrophobicity, charge and solubility of the peptide sequences obtained in S2.

3. The preparation method according to claim 1-2, characterized in that: PeptideRanker is used to predict the potential activity of peptides; Toxinpred is used to predict the toxicity, hydrophobicity, hydrophilicity, and charge of peptides; Innovagen is used to predict the solubility of peptides.

4. The preparation method according to claim 1, characterized in that: In S4, the molecular docking method is used to screen active peptides with inhibitory potential on breast cancer-related targets, including the following steps: (1) Acquisition of 3D structures: The 3D structures of ERα, PR, HER2, and EGFR were obtained from the RCSB database; (2) Construction of active peptide structure: Use ChemDraw and Chem3D to construct active peptide structure; (3) Molecular docking: After removing the ligands and water molecules from ERα, PR, HER2, and EGFR in step (1), nonpolar hydrogen and Gaussian charges were added together with the peptide sequence obtained in S2, and semi-flexible molecular docking of peptide with ERα, peptide with PR, peptide with HER2, and peptide with EGFR was performed using AutoDock 4.2 software; (4) After molecular docking, active peptides that show the best binding to breast cancer-related targets were screened out based on the binding energy results.

5. The preparation method according to claim 4, characterized in that: The active peptides that showed the best binding to estrogen receptor-positive breast cancer were IW, RPY, AF, ADR, VY, TAGW, SAGW, VVW, EY, and EK; The active peptides that showed the best binding to progesterone receptor-positive breast cancer were TAGW, SAGW, APVDA, VIPM, VPAL, VPVL, VVW, IW, EPY, and TW; The active peptides that showed the best binding to HER2-positive breast cancer were QW, PEK, IW, EDL, VVW, VIPM, SW, VPAL, VY, and TW; The active peptides that showed the best binding to triple-negative breast cancer were SAGW, VY, IW, AF, GY, SW, TAGK, AAH, VPVL, and TW.

6. The preparation method according to claim 1, characterized in that: In S5, the active peptides screened in step S4 are synthesized into small molecule peptides using the Fmoc solid phase synthesis method.

7. The preparation method according to claim 1, characterized in that: S6 is a mixture of one or more of the small molecule peptides synthesized by S5, curcumin, lycopene, catechins, and dextrin.

8. The bovine lactoferrin-derived anti-breast cancer small molecule peptide tablets prepared by the preparation method according to any one of claims 1 to 7.

Citation Information

Patent Citations

  • Micromolecule active peptide of stichopus japonicus source, and efficient screening method thereof

    CN109320589A

  • Screening of bovine whey protein source antioxidant peptide based on molecular simulation technology

    CN115631794A

  • Drug for cancer therapy

    US20060204501A1